ArticleBritish journal of pharmacology2019
Characterization of binding, functional activity, and contractile responses of the selective 5-HT
Article in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.CNS drugs · 2020Pooled it
- Trigeminovascular effects of propranolol in men and women, role for sex steroids.Annals of clinical and translational neurology · 2022Trial
- Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.Headache · 2021Trial
- Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.The journal of headache and pain · 2020Trial
- Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.Cephalalgia : an international journal of headache · 2020Trial
- Pharmacologic MRI Brain Imaging Studies of Serotonin 5-HTPharmacology research & perspectives · 2026Article
- From bench to bedside: relevant animal models across the migraine attack phases.The journal of headache and pain · 2026Review
- Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders.Journal of medicinal chemistry · 2026Review
- Epigenetics in migraine: the Junior Editorial Board Members' vision.The journal of headache and pain · 2025Review
- A comprehensive review on calcitonin gene-related peptide in the management of gastrointestinal disorders.Inflammopharmacology · 2025Review
- Stroke etiology and white matter burden in women with and without migraine.The journal of headache and pain · 2025Article
- Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study).Therapeutic advances in neurological disorders · 2025Article
- Male-female comparison of vasomotor effects of circulating hormones in human intracranial arteries.The journal of headache and pain · 2024Article
- Hallmarks of primary headache: part 1 - migraine.The journal of headache and pain · 2024Review
- Medication-Overuse Headache: Update on Management.Life (Basel, Switzerland) · 2024Review
- Health equity, care access and quality in headache - part 2.The journal of headache and pain · 2023Review
- Mode and site of action of therapies targeting CGRP signaling.The journal of headache and pain · 2023Review
- The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- The 5-HTNature reviews. Neurology · 2023Review
- Cardiovascular Disease and Migraine: Are the New Treatments Safe?Current pain and headache reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTriptans are 5-HT EXPERIMENTAL APPROACH: Binding and second messenger activity assays of lasmiditan and other serotoninergic agonists were performed for human 5-HT KEY
resultsLasmiditan showed high selectivity for 5-HT CONCLUSIONS AND IMPLICATIONS: Lasmiditan is a selective 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.